# Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma

> **NCT01470443** · PHASE3 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 240 (actual)

## Conditions studied

- Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01470443
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12-28
- **Primary completion:** 2016-12
- **Final completion:** 2020-12
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470443, "Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01470443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*